
- /
- Supported exchanges
- / TO
- / HLS.TO
HLS Therapeutics Inc (HLS TO) stock market data APIs
HLS Therapeutics Inc Financial Data Overview
HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally. The company's product portfolio includes Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; and Vascepa, an icosapent ethyl capsules for cardiovascular disease. It also distributes MyCare psychiatry lab assays; and MyCare Insite, a point-of-care device to measure patient drug levels. In addition, the company holds the Canadian rights of Trinomia, a cardiovascular therapeutic; and a portfolio of royalty interests of four healthcare products. HLS Therapeutics Inc. is headquartered in Etobicoke, Canada.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get HLS Therapeutics Inc data using free add-ons & libraries
Get HLS Therapeutics Inc Fundamental Data
HLS Therapeutics Inc Fundamental data includes:
- Net Revenue: 56 940 K
- EBITDA: 15 772 K
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2024-11-07
- EPS/Forecast: -0.2
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
HLS Therapeutics Inc News

HLS Therapeutics Announces CFO Departure
John Hanna appointed Interim CFO to replace departing CFO Tim Hendrickson TORONTO, Dec. 18, 2023 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused ...


HLS Therapeutics (TSE:HLS) shareholders have endured a 78% loss from investing in the stock three years ago
It's not possible to invest over long periods without making some bad investments. But you want to avoid the really big losses like the plague. So spare a thought for the long term shareholders of HLS...

Some HLS Therapeutics Inc. (TSE:HLS) Analysts Just Made A Major Cut To Next Year's Estimates
The latest analyst coverage could presage a bad day for HLS Therapeutics Inc. (TSE:HLS), with the analysts making across-the-board cuts to their statutory estimates that might leave shareholders a lit...

New REDUCE-IT® Analyses Show Vascepa® (Icosapent Ethyl) Associated with 29 Percent Relative Risk Reduction Compared with Placebo in Prespecified Subgroup of Patients with Metabolic Syndrome, but Without Diabetes at Baseline
Analysis Also Found Icosapent Ethyl Was Associated with a 41% Reduction in Total Events Compared with Placebo Subgroup Almost Exclusively Comprised of Patients with Established Cardiovascular Disease...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.